GO
Loading...

Enter multiple symbols separated by commas

Bristol-Myers Squibb Co

More

  • Bang for your buck: Where earnings surprises are Thursday, 23 Apr 2015 | 8:28 AM ET
    Traders on the floor of the New York Stock Exchange.

    Three sectors are seeing the biggest rallies following earnings reports. Where investors should place future bets.

  • April 17- A large study of Bristol-Myers Squibb Co's Opdivo treatment has been halted after proving the drug is effective against the most common form of lung cancer, the company said, positioning the medicine for far wider use than its already approved lung cancer and melanoma indications. AstraZeneca Plc, Pfizer Inc and other drugmakers are developing their...

  • Biotech investors brace for updates on key drugs Friday, 17 Apr 2015 | 1:44 PM ET
    Lab technician handling test tubes

    Biotech investors are going to be busy with new data on Alzheimer's drugs, cancer and genetic disorders on the way. Here's what analysts are watching.

  • Former Teva CEO's new gig at Ovid Therapeutics Thursday, 16 Apr 2015 | 6:10 AM ET

    After an abrupt departure, Former Teva CEO Jeremy Levin is now leading a start-up focused on rare neurological disorders.

  • April 15- The Medicines Co's intravenous blood clot preventer can be used in angioplasty procedures, an independent advisory panel to the U.S. Food and Drug Administration said on Wednesday. The recommendation follows a review published by FDA staff on Monday, which supported the approval of the drug. Cangrelor, which won European approval in March, was...

  • LONDON, April 15- Having seen off a hostile $118 billion bid launched a year ago by U.S. rival Pfizer, Anglo-Swedish company AstraZeneca is on the move-- quite literally. Chief Executive Pascal Soriot is making AstraZeneca more nimble as hopes build for its cancer pipeline, but he still has his work cut out to keep 2015 earnings above the floor needed to protect his...

  • April 13- An intravenous blood clot preventer developed by The Medicines Co should be approved by the U.S. Food and Drug Administration, FDA staff reviewers concluded. The FDA rejected the blood thinner in April last year, after its reviewers took issue with the way a pivotal trial, called Champion- Phoenix, was conducted, and asked the company to reanalyze its...

  • NEW YORK, April 6- U.S. stocks rose on Monday as expectations the Federal Reserve could hold off longer on raising U.S. interest rates offset concerns over Friday's surprisingly weak monthly jobs report. U.S. stock markets were closed for the Good Friday holiday. "The weekend allowed market participants to see the positive side of the weak Friday number, which is...

  • NEW YORK, April 6- U.S. stocks rose on Monday as expectations the Federal Reserve could hold off longer on raising interest rates offset concerns over Friday's surprisingly weak jobs report. "The weekend allowed market participants to see the positive side of the weak Friday number, which is that rates probably aren't going to rise very quickly," said Rick Meckler,...

  • NEW YORK, April 6- U.S. stocks rose on Monday as expectations the Federal Reserve will push any interest rate increases further into the year offset concerns over Friday's surprisingly weak jobs report. Labor Department data showed U.S. employers last month added 126,000 jobs, the lowest number in more than a year and well below expectations.

  • NEW YORK, April 6- U.S. stocks rose on Monday as expectations the Federal Reserve will push any interest rate increases further into the year offset concerns over faltering economic growth spurred by a surprisingly weak jobs report on Friday. Labor Department data showed U.S. employers last month added 126,000 jobs, the lowest in more than a year and well below...

  • UniQure's shares jumped more than 55 percent on Monday after Bristol-Myers said it would pick up a 4.9 percent stake in the company. UniQure's gene therapy drug, Glyberan, went on sale last year priced at 1.1 million euros. Bayer AG struck a gene therapy deal with Dimension Therapeutics in June, while France's Sanofi SA has a long-standing tie-up with Oxford...

  • *Herbalife shares fall after investigation report. NEW YORK, April 6- U.S. stocks edged up on Monday as expectations the Federal Reserve will push any interest rate increases further into the year offset concerns over faltering economic growth spurred by a surprisingly weak jobs report on Friday. "The market seems to be very confused whether bad or good news is...

  • *Herbalife shares fall after investigation report. NEW YORK, April 6- U.S. stock index futures fell in low volume on Monday, putting Wall Street on track for a lower open on the first trading session since Friday's surprisingly weak jobs data. *The jobs data was released on Good Friday, when Wall Street was closed.

  • FRANKFURT, April 1- Roche, the world's largest cancer drugmaker, is ready to collaborate with rivals to find new combination therapies for multi-pronged treatments, its chief executive said. Roche is vying with rivals such as Bristol-Myers Squibb, Merck& Co and AstraZeneca to develop such immuno-oncology therapies that harness the power of the body's immune...

  • Hottest dividend stocks of 2015 Tuesday, 24 Mar 2015 | 2:58 PM ET
    A trader works on the floor of the New York Stock Exchange.

    CNBC screened the large cap S&P 500 index to see where the hottest parts of the dividend stock market have been.

  • March 24- Merck& Co Inc said on Tuesday that it would stop a large study of its Keytruda melanoma treatment early because an independent monitoring committee determined the drug succeeded in its goal of prolonging survival in previously untreated patients at advanced stage of the disease. The medicine, a PD-1 inhibitor that works by taking the brakes off the...

  • March 24- Bristol-Myers Squibb said on Tuesday it had agreed to acquire rights to a Novo Nordisk immune system research program, which the Danish company is divesting as it focuses further on diabetes care. The project aims to modulate the innate immune system as a therapy for autoimmune diseases and the U.S. drugmaker said it fitted with its long-standing...

  • *Up from three potential $1 billion- plus drugs in 2014. LONDON, March 23- Bristol-Myers Squibb, Sanofi and Novartis have the three top new drugs set to reach the market in 2015, among 11 products each with $1 billion- plus sales potential, according to a Thomson Reuters analysis. In total, 11 of the many new drugs set for launch in 2015 are expected to generate $1 billion-...

  • *Up from three potential $1 billion- plus drugs in 2014. LONDON, March 23- Bristol-Myers Squibb, Sanofi and Novartis have the three top new drugs set to reach the market in 2015, among 11 products each with $1 billion- plus sales potential, according to a Thomson Reuters analysis. In total, 11 of the many new drugs set for launch in 2015 are expected to generate $1 billion-...